Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cryotherapy followed by tirbanibulin vs cryotherapy followed by placebo for actinic keratosis of the scalp and forehead
2023-509931-15-00Phase 4Authorised
- Sponsor
- CHU de Lille
- Start
- Jun 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial in actinic keratosis (AK) comparing Cryotherapy + tirbanibulin ointment (Klisyri) zone with Cryotherapy + placebo ointment zone (2 arms). Primary endpoint: Complete response rate of actinic keratosis at 8 months. Planned start Jun 2024; status: authorised.
02
Drugs
tirbanibulin
03
Conditions
actinic keratosis (AK)
Beyond the preview
Go deeper on 2023-509931-15-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-509931-15-00.